Seth Klarman: portfolio of Baupost Group

Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.

Source: 13F filing with the US Securities and Exchange Commission dated Aug 11, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q2 2017. Go to the latest filing (Q3 2026)

8.7B USDQ2 2017
Total value of stock positions
8.7B USD
Positions
39
Share of the ten largest
72.6%

The ten largest positions Q2 2017

  1. Cheniere Energy Inc 11.6%▼ −4.6%
  2. Synchrony Financial 10.0%▲ +65.8%
  3. Viasat Inc 10.0%unchanged
  4. Colony Northstar Inc 7.8%unchanged
  5. Allergan PLC 6.8%unchanged
  6. Qorvo Inc 6.6%▲ +25.3%
  7. Twenty First Centy Fox Inc 6.2%unchanged
  8. Antero Res Corp 5.3%▲ +45.9%
  9. Theravance Biopharma Inc 4.2%unchanged
  10. Pbf Energy Inc 4.0%unchanged
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 12.7B USD).
Choose a quarter (54 filings)

All positions Q2 2017

Positions Q2 2017 per 13F filing, 7 of 7
Symbol Weight Shares Reported value Change Held since
SYF Synchrony Financial 10.0% 29,295,030 873.6M USD +65.8% increased Q3 2016 4 quarters
Qorvo Inc 6.6% 9,000,000 569.9M USD +25.3% increased Q1 2017 2 quarters
Antero Res Corp 5.3% 21,170,996 457.5M USD +45.9% increased Q3 2014 12 quarters
Express Scripts Hldg Co 1.9% 2,556,891 163.2M USD +108.1% increased Q1 2017 2 quarters
CAH Cardinal Health 1.8% 2,030,000 158.2M USD +97.1% increased Q4 2016 3 quarters
Forward Pharma A/S 1.5% 6,364,059 129.4M USD +14.1% increased Q4 2014 11 quarters
Paratek Pharmaceuticals Inc 0.7% 2,394,498 57.7M USD +17.1% increased Q4 2014 11 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Plus 2 positions in convertible bonds and bonds worth 55.9M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Theravance Biopharma Inc principal 30.0M USD 40.4M USD
  • Theravance Inc principal 17.0M USD 15.5M USD

Breakdown by sector

  • Financials 10.0%
  • Technology 7.3%
  • Health Care 1.8%
  • Industrials 0.2%
  • not in our coverage 80.6%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close